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Abstract
Breast cancer is highly aggressive and is the leading cause of cancer-related mortality in women in developed
countries. The ETS proto-oncogene 1 (Ets1) has versatile roles during the cellular processes of cancer development. It is
often highly expressed in breast cancers and mediates migration and invasion of human breast cancer cells. However,
underlying mechanisms of Ets1 gene expression is still ambiguous. Here, we identiﬁed a core-regulatory element (CRE)
located in the Ets1 promoter region (−540/−80 bp from TSS) that contains elements responsible for associating with
NFATs and NF-κBs. Compared with the less metastatic breast cancer cells, metastatic breast cancer cells (MDA-MB-231)
show open chromatin conﬁgurations in the CRE, which facilitates direct binding of NFATc2 and/or NFKB1/RELA
complex to trans-activate Ets1 transcription. Moreover, enhanced level of Nfatc2 and Nfkb1 positively correlated with
Ets1 expression in the human breast cancer specimens. Deletion of the CRE region by CRISPR/Cas9 system resulted in
signiﬁcant reduction in Ets1 expression, which led to alterations of Ets1-mediated transcription programs including
tumor invasiveness-related genes. Proper regulation of Ets1 gene expression by targeting the NFATc2 and NFKB1/RELA
interaction could be a potential therapeutic target for Ets1-mediated metastatic breast cancer.
Introduction
Cancer cells have unique programs to potentiate
tumorigenesis at the transcriptional, post-transcriptional
and post-translational steps1. The ETS proto-oncogene 1
(Ets1) is known as an oncogenic transcription factor. Ets1
contributes to the development and progression of diverse
tumors such as epithelial tumor, sarcomas, and astro-
cytomas2–4 by directly regulating the expression of extra-
cellular matrix remodeling factors such as MMP-1, MMP-
3 and MMP-9, and uPA (urokinase-type plasminogen
activator)5–8. Ets1 also promotes the angiogenic process of
tumor cells by enhancing the expression of vascular
endothelial growth factor (VEGF) receptor, Neuropilin-1
(Nrp1), and angiopoietin-2 (Ang2)9–12. Ets1 also regulates
epithelial–mesenchymal transition (EMT) in epithelial and
carcinoma cells13,14. Moreover, high level of Ets1 expres-
sion was closely linked with strong metastatic potential
and poor clinical prognosis in various types of cancers15–
17. Accordingly, Ets1 could be a conceivable therapeutic
target especially in the triple-negative/basal-like breast
cancers (TN/BLBC) that show Ets1high expression proﬁle
compared with non-TNBC cells18.
Interestingly, however, underlying mechanisms of
transcriptional regulation of Ets1 gene expression is
poorly characterized in cancer cells. Previous studies were
mainly focused on understanding how Ets1 expression is
regulated by factors within tumor microenvironment such
as hepatocyte growth factor (HGF), basic ﬁbroblast
growth factor (bFGF), vascular endothelial growth factor
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(VEGF), Platelet-derived growth factor-BB (PDGF-BB),
and transforming growth factor beta (TGFβ)19–22. These
extrinsic factors enhance Ets1 transcription through
subsequent activation of downstream signaling pathways
including MEK/ERK1/2, PI3K (phosphoinositol-3-
kinase)/AKT, protein kinase C (PKC), and calcium sig-
naling19–23. Under such conditions, several transcription
factors (such as AP-1, Ets1, and hypoxia-mediated HIF1α
[HIF1α]) are known to directly upregulate Ets1 tran-
scription in cancer cells24–26. However, it is still unclear
which types of transcriptional factors and cis-acting reg-
ulatory elements cooperatively regulate transcriptional
activity of Ets1 gene expression, especially in breast cancer
cells.
In this study, we investigated the transcriptional and
epigenetic regulation of Ets1 gene expression in meta-
static breast cancer cells. We identiﬁed a core-regulatory
element (CRE) on the Ets1 promoter and elucidated its
functional importance in tumor invasiveness. Compared
with less metastatic cells (MCF-7), metastatic breast
cancer cells (MDA-MB-231) have relatively open chro-
matin structure on the CRE, which facilitates direct
binding of NFATc2 and NFKB1/RELA to enhance Ets1
expression and invasiveness of metastatic breast cancers,
accordingly.
Results
Ets1 expression is regulated at the transcriptional level in
breast cancer cells
To understand the transcriptional regulation mechan-
isms of Ets1 expression in breast cancer cells, we ﬁrst
analyzed Ets1 transcript level among various breast cancer
cell lines. Based on Ets1 level, cancer cells were divided
into two categories: Ets1high and Ets1low cell lines (Fig. 1a,
Supplementary Figures S1a, b). We chose three repre-
sentative cell lines, MCF-7 (Ets1low), MDA-MB-468
(Ets1low), and MDA-MB-231 (Ets1high), and conﬁrmed the
expression status of Ets1 by qRT-PCR and Immuno-blot
(Fig. 1b, c) (Supplementary Figures S1a, b). Since Ets1
expression is correlated with invasiveness of tumor cells27,
we compared the invasive properties of MCF-7 and
MDA-MB-231 by invasion assay. Indeed, MDA-MB-231
(Ets1high) cells were more invasive than MCF-7 (Ets1low)
cells (Fig. 1d). To conﬁrm this observation is Ets1-
dependent, we compared non-metastatic MDA-MB-468
cells with MDA-MB-231 cells, which share similar hor-
monal status. Similar to the MCF-7 cells, MDA-MB-468
cells showed reduced Ets1 expression with less invasive
properties than MDA-MB-231 cells (Supplementary Fig-
ures S1a, b).
Next we tested which types of stimuli trigger Ets1
expression in MDA-MB-231 cells. To mimic tumor
microenvironment (TME), MDA-MB-231 cells were sti-
mulated with various tumorigenic factors such as TGFβ,
HGF, and PMA and Ionomycin28–30. Co-treatment with
PMA and Ionomycin (P/I) induced the highest level of
Ets1, indicating synergy between PKC and calcium (Ca2+)
pathways (Fig. 1e, f). Compared with MCF-7 cells, MDA-
MB-231 cells showed signiﬁcantly enhanced Ets1
expression in mRNA and protein levels upon PMA/
Ionomycin stimulation (Fig. 1g, h). Treatment of the
transcription inhibitor actinomycin D abolished PMA/
Ionomycin induced Ets1 expression, indicating that Ets1
expression is regulated at the transcriptional level in the
metastatic MDA-MB-231 breast cancer cells (Fig. 1i).
Identiﬁcation of core-regulatory element (CRE) and CRE-
binding transcription factors involved in Ets1 expression
To identify the core-regulatory element (CRE), we
serially deleted the Ets1 promoter region and tested its
effect on trans-activation of Ets1 expression measured by
reporter activity. As shown in Fig. 2a, deletion of −540 to
−80 bps from transcription start site (TSS) signiﬁcantly
reduced the luciferase activity, indicating the pivotal role
of this locus for the trans-activation of Ets1 expression.
Using an ECR browser31, we identiﬁed NFATs and NF-κB
transcription factors could potentially bind to this locus to
activate Ets1 expression (Supplementary Figures S2a, b).
Indeed, among the diverse transcription factors tested, co-
transfection of NFATc2 or NFKB1/RELA resulted in
highest Ets1 promoter activity (Fig. 2b, Supplementary
Figure S2c). In contrast, mutations of NFAT or NF-κB
binding sequences completely abrogated Ets1 promoter
activity (Fig. 2c). We also conﬁrmed that knockdown (KD)
of these factors (Nfatc2, Nfkb1, and Rela) signiﬁcantly
reduced Ets1 expression (Fig. 2d–f). Moreover, triple
knockdown (TKD) of these factors most signiﬁcantly
reduced Ets1 expression (Fig. 2e, f) and decreased the
invasive properties of MDA-MB-231 cells (Fig. 2g). These
results indicate NFATc2, NFKB1 and RELA cooperatively
enhance Ets1 expression through CRE (−80 to −520bps
from TSS) region in the metastatic MDA-MB-231 breast
cancer cells.
NFATc2 and NFKB1/RELA regulate Ets1 expression in
metastatic breast cancer cells
To gain further mechanistic insight on the role of
NFATc2 and NFKB1/RELA on Ets1 expression in MCF-7
(Ets1low) and MDA-MB-231 (Ets1high) cells, we next
compared the expression status of NFATc2 and NFKB1/
RELA in these cell lines. MDB-MB-231 cells expressed
much higher levels of NFATc2 in mRNA and protein
(total and nuclear) compared with MCF-7 cells (Fig. 3a, b,
d). On the other hand, no signiﬁcant differences were
observed in NFKB1 and RELA levels between these cells
(Fig. 3a, b). Similar to MCF-7 cells, non-metastatic triple-
negative MDA-MB-468 cells showed reduced expression
of NFATc2 levels and invasion related genes including
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Eng and Mmp14 compared to MDA-MB-231 cells (Sup-
plementary Figures S1c, d).
Next, we tested whether differential expression of
NFATc2 or NF-κBs has any correlation with Ets1
expression in human breast cancer specimens by analyz-
ing The Cancer Genome Atlas (TCGA) database that
provide unbiased large-scale transcriptome data for var-
ious human cancer32. Indeed, expression level of Nfatc2
Fig. 1 Comparative analyses of Ets1 expression between metastatic MDA-MB-231 and less metastatic MCF-7 breast cancer cells. a Analysis
of Ets1 expression proﬁle in 59 breast cancer cell lines by Cancer Cell Lines Encyclopedia (CCLE). b, c Analyses of Ets1 transcripts and protein levels by
qRT-PCR (b) and Immuno-blot (c) in unstimulated condition. d Cells were stained with crystal violet and representative images were obtained from
in vitro invasion assay using 10% FBS as chemoattractant. Scale bar: 100 m. e Metastatic MDA-MB-231 cells were treated with indicated stimuli for 6 h
and relative levels of Ets1 transcripts normalized against Hprt are shown. f Effect of PMA (p), Ionomycin (i) and their combination (p/i) on Ets1
transcripts levels determined by qRT-PCR. g, h Comparative analysis of Ets1 transcripts and protein level between the cells in response to PMA/
Ionomycin (p/i) stimulation. Data are presented as mean ± SD. Two-way ANOVA with Bonferroni post-tests showed a signiﬁcant difference of Ets1
expression. i Effect of actinomycin D (Act D) treatment in MDA-MB-231 cells on Ets1 transcripts and protein levels determined by qRT-PCR and
Immuno-blot, respectively. Values in b, d, f, e, and i are means ± SD. One-way ANOVA with Bonferroni correction indicated a signiﬁcant difference. b–
i Data shown are representative of more than three independent experiments with similar results. N.D. not detected. *p < 0.05, **p < 0.01, and ***p <
0.001
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(Spearman r= 0.5183, ***p < 0.0001) and Nfkb1 (Spear-
man r= 0.3276, ***p < 0.0001) but not Rela showed cor-
relative expressions with Ets1 levels in human specimens
(Fig. 3c). We also compared nuclear levels of NFATc2,
NFKB1, and RELA levels between the cells. Compared
with MCF-7 cells (Ets1low), MDA-MB-231 (Ets1high) cells
showed signiﬁcantly higher levels of NFATc2, NFKB1,
and RELA in the nucleus upon PMA/Ionomycin stimu-
lation (Fig. 3d). Forced expression of NFATc2, NFKB1/
RELA in MCF-7 cells signiﬁcantly enhanced Ets1
expression and invasiveness (Fig. 3e, Supplementary Fig-
ure S3a). Overexpression of Ets1 also enhanced the
invasive capacity of MCF-7 cells (Supplementary Figure
S3b). Next, we performed ChIP assay to measure the
binding of these factors to CRE region between the cells.
Compared with MCF-7 cells (Ets1low), MDA-MB-231
(Ets1high) cells showed higher binding of NFATc2 as well
as NFKB1/RELA to the CRE region (Fig. 3f). In addition,
overexpression of NFATc2 and NFKB1/RELA increased
the binding of these factors to the CRE region in MCF-7
cells (Supplementary Figure 3c). These results suggest
that cellular availability as well as relative enrichment of
NFATc2 and NFKB1/RELA to the CRE region mediate
differential Ets1 expression between MDA-MB-231
(Ets1high) and MCF-7 cells (Ets1low).
Permissive chromatin architecture at the promoter is
required for Ets1 expression
Epigenetic abnormality in various cancer-related genes
is often involved in enhanced tumorigenesis33,34. To
compare the chromatin architecture between the MDA-
MB-231 (Ets1high) and MCF-7 cells (Ets1low), we have
performed chromatin accessibility by real-time PCR
(CHART-PCR). Compared with MCF-7 cells (Ets1low),
MDA-MB-231 (Ets1high) cells showed more open chro-
matin structure at the Ets1 promoter region (Supple-
mentary Figure S4a). Next we compared epigenetic status
of histone modiﬁcation and DNA methylation between
the cells. First we analyzed ChIP-seq data set35 for
H3K27Ac (active chromatin) and H3K27me3 (inactive
chromatin) in the Ets1 genomic locus between the cells.
Compared to MCF-7 cells, MDA-MB-231 cells showed
highly enriched H3K27Ac but decreased levels of
H3K27me3 (Fig. 4a). By performing ChIP analysis, we
conﬁrmed that the Ets1 locus in MDA-MB-231 cells is
enriched for chromatin modiﬁcations associated with
active gene transcription (H3Ac). On the other hand,
chromatin modiﬁcations associated with repressed gene
expression are under-represented (H3K9me3 and
H3K27me3) (Fig. 4b).
Since DNA methylation is another epigenetic mechan-
ism to control gene expression36, we compared DNA
methylation status of individual CpG sites localized in
CRE by bisulﬁde sequencing. All of nine CpG sites were
highly methylated in MCF-7 but demethylated in MDA-
MB-231 regardless of PMA/Ionomycin stimulation (Fig.
4c). We tested whether treatment of Decitabine (a DNA
methyl-transferase inhibitor) or TSA (a HDAC inhibitor)
could enhance Ets1 expression in MCF-7. Decitabine but
not the TSA treatment enhanced Ets1 expression in
MCF-7 (Supplementary Figures S4b, c). Moreover, Deci-
tabine treatment increased invasiveness of MCF-7 cells
and enhanced the binding efﬁciency of NFKB1 and RELA
to CRE region (Supplementary Figures S4d, e). These
results collectively suggest that chromatin architecture at
the Ets1 promoter (CRE region) in MCF-7 cells is in a
“less permissive” but not a “non-permissive” state.
To test whether differential DNA methylation status
between the cells is due to changes in level of DNA
methyl transferases, we analyzed a publicly available
RNA-seq data set37. Compared with MDA-MB-231 cells,
MCF-7 cells were found to express signiﬁcantly higher
levels of DNA methyl-transferase (Dnmt3a and Dnmt3b)
but lower levels of APOBEC family genes (Fig. 4d, e).
APOBEC is known as a cytidine deaminases and its dys-
regulation causes mutations in numerous cancer types.
Furthermore, MCF-7 cells showed higher binding of
DNMT3A and DNMT3B on CRE region (Supplementary
(see ﬁgure on previous page)
Fig. 2 Identiﬁcation of core-regulatory element (CRE) and CRE-binding transcription factors involved in Ets1 expression. a Schematic
diagram of the genomic position and size of the deletion constructs of promoter region of Ets1 gene are shown. b MDA-MB-231 cells were
transfected with Ets1 promoter-Luc reporter vector (540 bp) and together with indicated combinations (minus, plus) of expression vectors. Relative
luciferase activity was measured. c MDA-MB-231 cells were transfected with Ets1 promoter-Luc (540 bp) vector or vectors mutated in the NFAT or
NFAT/NFKB binding sites (multiply: mutation site). Relative luciferase activity in response to PMA/Ionomycin stimulation was measured. b, c Relative
luciferase activities relative to the expression of Renilla luciferase plasmid (hRluc) are calculated as fold difference relative to the control value. d, e
Effects of knockdown of indicated transcription factors on the expression of Ets1. MDA-MB-231 cells were transfected with mock siRNAs or siRNAs for
indicated transcription factors (NFATc2, NFKB1 and RELA) (d) or triple combination of them (TKD) (d, e). Knockdown efﬁciency on the level of
transcription factors by individual siRNAs or TKD siRNAs was conﬁrmed by Immuno-blot (f) and band intensity of Immuno-blot was quantiﬁed by
ImageJ software. g Knockdown of individual siRNAs or TKD siRNAs on invasive properties of MDA-MB-231 cells by invasion assay. Scale bar: 100 m.
Data are presented as mean ± SD. One-way ANOVA with Bonferroni correction indicated a signiﬁcant difference of invaded cells. a–c, f Data are
presented as mean ± SD. Two-way ANOVA with Bonferroni post-tests showed a signiﬁcant difference. a–g Data shown are representative of more
than three independent experiments with similar results. *p < 0.05, **p < 0.01, and ***p < 0.001
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Fig. 3 NFATc2 and NFKB1/RELA regulate Ets1 expression in breast cancer cells. a, b Comparison of NFATc2, NFKB1, and RELA protein and
transcript levels in whole cell lysates of MCF-7 and MDA-MB-231 cells determined by a Immuno-blot and b qRT-PCR normalized against Hprt. Data
are presented as mean ± SD. One-way ANOVA with Bonferroni correction indicated a signiﬁcant difference of expression. c Scatterplots and
Spearman’s rank correlation from TCGA database. Correlation between mRNA expression of Ets1 with Nfatc2, Nfkb1, and Rela. Each symbol represents
an individual human specimen. a, d Representative Immuno-blot for the total and nuclear (NE) protein levels in unstimulated conditions or cells
stimulated for indicated time points. ACTIN and LaminB1 served as loading control for total and NE, respectively. e Effect of overexpression of
transcription factors (NFATc2 and NFKB1/RELA) on Ets1 expression in MCF-7 cells determined by Immuno-blot. f Relative enrichment of transcription
factors to the CRE region determined by ChIP analysis with speciﬁc antibodies for NFATc2, NFKB1, and RELA. Results are presented relative to input
DNA. Data are presented as mean ± SD. Two-way ANOVA with Bonferroni post-tests showed a signiﬁcant difference of binding efﬁciency of NFATc2,
NFKB1, and RELA between MCF-7 and MDA-MB-231 cells. a, b, d, e, f Data shown are representative of more than three independent experiments
with similar results. *p < 0.05, **p < 0.01, and ***p < 0.001 (unpaired t-test)
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Figure S5a) while MDA-MB-231 cells show no DNMT
association to Ets1 locus due to their low expression (data
not shown). We also tested whether levels of Ets1
expression could be altered upon overexpression of
DNMT3A/3B or APOBEC3C in MDA-MB-231 and
MCF-7 cells, respectively. Indeed, overexpression of
DNMT3A/3B in MDA-MB-231 cells decreased Ets1
expression, whereas overexpression of APOBEC3C in
MCF-7 cells slightly increased Ets1 expression (Supple-
mentary Figures S5b, c). These results in part suggest
availability of DNA methyl transferases can affect the level
of Ets1 transcription.
We also questioned whether this ﬁnding could be
generalized in various breast cancer cell lines (n= 59).
Indeed, analysis of Cancer Cell Line Encyclopedia con-
ﬁrmed that Ets1 expression was negatively correlated with
Dnmt3a (Spearman r=−0.4139, **p= 0.0011) and
Dnmt3b (Spearman r=−0.5878, ***p < 0.0001) but posi-
tively with Apobec3c (Spearman r= 0.6239, ***p < 0.0001)
(Fig. 4f). Consistent with human cell line data, Ets1
expression was negatively correlated with Dnmt3a and
Dnmt3b in normal specimens, while Ets1 level is positively
correlated with Apobec3c in human breast cancer speci-
mens (Supplementary Figure S5d). These results indicate
that Ets1 expression is epigenetically regulated in breast
cancer.
Deletion of CRE region reduces Ets1 expression and tumor
invasiveness
To validate the functional role of NFAT and NF-κB
binding sites (−540bp to −270bp) within the CRE region
(−540 to −80 from TSS) in Ets1-mediated tumorigenesis,
we deleted the region by a CRISPR/Cas9 based KO system
in metastatic MDA-MB-231 cells (Supplementary Figures
S6a, b). Compared with wild-type MDA-MB-231 cells
(WT), CRE-deleted cells (ΔCRE) showed lower levels of
Ets1 expression in mRNA and protein (Fig. 5a, b). We
then compared transcriptome proﬁles between WT and
ΔCRE cells by RNA-seq analysis. ΔCRE cells showed
altered expression of numerous genes (DEGs: p-value <
0.05; 0 h - Up: 285 and Down: 179, 6 h - Up: 627 and
Down: 954, 24 h - Up: 544 and Down: 745) (Fig. 5c).
Gene-annotation enrichment analysis (DAVID) showed
that ΔCRE cells had alterations in cell adhesion and
angiogenesis programs (Fig. 5d). Indeed, we found that
ΔCRE cells express much lower level of Eng and Mmp14
(Fig. 5e), critical factors for cell adhesion38,39. In addition,
by performing ChIP assay, we conﬁrmed the possibility
that direct binding of Ets1 to the promoters of those
target genes regulates expression levels (Fig. 5f). Analysis
of human breast cancer specimens further conﬁrmed this
possibility. We analyzed 1000 human breast cancer spe-
cimens (Fig. 5g) and 59 human breast cancer cell lines
(Fig. 5h) and found that levels of Ets1 expression is well-
correlated with Eng and Mmp14 levels, accordingly (Fig.
5g, h).
To verify the functional role of CRE in Ets1-mediated
metastasis of breast cancer cells, ﬁrst we performed
in vitro invasion assay. Compared with WT MDA-MB-
231, ΔCRE cells showed signiﬁcantly reduced invasive
capacity (Fig. 5i). To further conﬁrm whether CRE dele-
tion reduces tumor invasiveness in vivo, nude mice were
injected intravenously into the tail vein with either ΔCRE
or WT MDA-MB-231 cells. After 6 weeks, tumor inva-
siveness was compared between the groups. Indeed,
ΔCRE-injected mice showed a signiﬁcant reduction of
metastasis nodules in the lungs compared with mice
injected with WT cells (Fig. 5j). Interestingly, Ets1 over-
expression in ΔCRE cells signiﬁcantly increased their
invasive properties but was still less compared to the
parent WT MDA-MB-231 cells (Supplementary Figures
S7a, b). Moreover, overexpression of both NFATc2 and
NFKB1/RELA into ΔCRE cells increased Ets1 expression
and their invasive properties, but was still less compared
(see ﬁgure on previous page)
Fig. 4 Close association of epigenetic status with Ets1 level. a ChIP-seq analysis of H3K27Ac and H3K27me3 at Ets1 promoter locus in MCF-7
(blue line) and MDA-MB-231 (red line) cells. b ChIP analysis of active marker (H3Ac) and inactive markers (H3K9me3 and H3K27me3) at Ets1 promoter
locus under unstimulated or P/I stimulation conditions. The data from each replicate were normalized to the input control and the graphs represent
fold enrichment of the indicated proteins to control antibody at the designated locus. Data are presented as mean ± SD. Two-way ANOVA with
Bonferroni post-tests showed a signiﬁcant difference of binding efﬁciency of H3Ac, H3K9me3, and H3K27me3 between MCF-7 and MDA-MB-231
cells. c DNA methylation status in the nine CpG sites (−375 or −534) was analyzed by bisulﬁte sequencing under unstimulated or stimulated (P/I)
condition. Closed and open circles indicate methylated and unmethylated CpG sites, respectively. Bar graphs represent percentage methylation. Data
are presented as mean ± SD. Two-way ANOVA with Bonferroni post-tests showed a signiﬁcant difference of DNA methylation status. d Heatmap of
RNA-sequencing data showing relative expression of DNA methylation-related and demethylation-related factors. e Analysis of relative expression
levels in transcripts normalized against Hprt and proteins by qRT-PCR and Immuno-blots, respectively. Data are presented as mean ± SD. One-way
ANOVA with Bonferroni correction indicated a signiﬁcant difference of expression. f Scatterplots and nonparametric Spearman’s rank correlation (ρ)
analysis with corresponding p-values correlation analysis from CCLE. Correlation between Ets1 and DNA methylation-related genes (Dnmt3a, Dnmt3b,
and Apobec3c) in mRNA. Each symbol represents an individual human breast cancer cell line. Green circle: MCF-7 cells; Red circle: MDA-MB-231 cells.
b, c, e Data shown are representative of more than two independent experiments with similar results. *p < 0.05, **p < 0.01, and ***p < 0.001 (unpaired
t-test)
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to the WT MDA-MB-231 cells (Supplementary Figures
S7c, d). Collectively, these data demonstrate a critical role
of CRE in Ets1 gene expression and Ets1-mediated
metastasis of breast cancer cells.
Discussion
In this study, we have found that Ets1 gene expression is
regulated epigenetically as well as by the crosstalk
between NFATc2/NF-κBs and core-regulatory element
(CRE) located in the Ets1 promoter. Deletion of CRE
region down-regulated Ets1 expression and, consequently,
reduced breast cancer progression by altering cancer-
associated genetic programs.
Ets1 expression and function are regulated by diverse
mechanisms. Previous studies reported that Ets1 gene
expression is transcriptionally regulated by several tran-
scription factors including Ets1, AP-1, AP-2, and Oct in
human T cell and B cell lines24,40,41. In this study, we
identiﬁed the core-regulatory element (CRE) region in the
Ets1 promoter that contains binding sequences for
NFATs and NF-κBs. Binding of NFATc2 and NFKB1/
RELA heterodimer to the CRE region synergistically
contribute to the expression of Ets1. NFATs and NF-κBs
factors are reported as downstream targets of calcium and
PKC signaling, respectively, and affect expression level of
their target genes associated with tumor pathogenesis42–
47. Our ﬁnding support the previous reports that calcium
signaling affects multiple cellular responses in the tumor
microenvironment48,49. Ca2+-NFAT signaling is asso-
ciated with growth and development of malignant breast
cancer43. Ca2+ ionophore, ionomycin synergizes with
PMA in enhancing the activation of PKC50. In accordance
with this notion, we observed that Ets1 expression was
synergistically increased upon PMA/Ionomycin (P/I) sti-
mulation (Fig.1f).
Physical binding of transcription factors to the reg-
ulatory region requires permissive chromatin archi-
tecture. Moreover, epigenetic changes including aberrant
DNA methylation are tightly linked to cancer develop-
ment51. For example, DNMT3A mutation signiﬁcantly
reduced methylated DNA levels and reduced survival rate
in AML patients by causing enhanced expression of
HOXB genes52. Furthermore, alteration in APOBEC
expression level also caused increased frequencies of
TP53 mutation derived-inactivation in breast cancer
development53. Although Activation-induced cytidine
deaminase (AID)/APOBEC cytosine deaminases have
been shown to implicate in active DNA demethylation54,
it is not clear whether aberrant DNA demethylation
causes uncontrolled gene regulation in cancer develop-
ment. We found that metastatic MDA-MB-231 (Ets1high)
cancer cells have active chromatin status in the Ets1 locus
compared to less metastatic MCF-7 (Ets1low) cells. These
ﬁndings suggested that changes in level of epigenetic
regulators regulate Ets1 expression. DNA methylation and
demethylation are mediated by DNA methyl-transferase
enzymes (DNMT1, 3A, and 3B) and TET enzymes (TET1,
2, and 3)/DNA deaminase (AID/APOBEC family),
respectively. In depth analysis of gene expression proﬁles
showed that indeed, MCF-7 (Ets1low) cells express much
higher levels of DNA methyl-transferase such as Dnmt3a
and Dnmt3b, while Apobec3c levels were increased (Fig.
4d, e). Based on these ﬁndings, we believe that levels of
DNMT3A and DNMT3B regulate methylated status of
CRE region, leading to differential Ets1 expression
between metastatic versus less metastatic cells.
Deletion of NFAT and NF-κB binding sites (−540 bp to
−270 bp from TSS) within the CRE region (−540 to −80)
in metastatic breast cancer cells (ΔCRE cells) diminished
Ets1 levels and reduced expression levels of invasion
(see ﬁgure on previous page)
Fig. 5 Deletion of CRE region reduces Ets1 expression and tumor invasiveness. a, b Comparative analysis of Ets1 expression levels in transcripts
and protein between WT and CRE-deleted MDA-MB-231 (ΔCRE) cells determined by qRT-PCR and Immuno-blot. Transcript levels were normalized
against Hprt and actin served as loading controls, respectively. Data are presented as mean ± SD. Two-way ANOVA with Bonferroni post-tests showed
a signiﬁcant difference of Ets1 expression. c Heatmap of RNA-sequencing data showing differentially expressed genes (DEGs) in WT and ΔCRE MDA-
MB-231 cells. d GO-term enrichment using DAVID “Biological functions” category. Shown are the top ﬁve up and down-regulated functions based on
–log2(p value). e Comparison of expression levels of Ets1 target genes between WT and ΔCRE cells. f ChIP-PCR was performed to detect Ets1
enrichment on the promoter regions of Eng and Mmp14 genes in MDA-MB-231 cells 2 h after stimulation. Fold enrichment compared with input is
shown. Data are representative of two individual experiments. Bars represent averages from triplicate PCR reactions as mean ± SD. One-way ANOVA
with Bonferroni correction indicated a signiﬁcant enrichment of Ets1; *p < 0.05; **p < 0.01; ***p < 0.001. g Scatterplots and nonparametric Spearman’s
rank correlation analysis with corresponding P-values correlation analysis from TCGA. Correlation between Ets1 and target genes (Eng and Mmp14) in
mRNA levels. Each symbol represents an individual BRCA sample. h Scatterplots and nonparametric Spearman’s rank correlation analysis with
corresponding p-values correlation analysis from CCLE. Correlation between Ets1 and target genes (Eng and Mmp14) in mRNA levels. Each symbol
represents an individual human breast cancer cell line. i Cells were stained with crystal violet and representative images were obtained from in vitro
invasion assay using 10% FBS as chemoattractant. Cells were stained with crystal violet. Scale bar: 100 m. j Representative images (left) and numbers
of metastasis nodules (right) of mouse lungs obtained from 6 weeks after tail vein injections of WT or ΔCRE cells (each 5 × 105) into eight female nude
mice, respectively. i, j Data are presented as mean ± SD. One-way ANOVA with Bonferroni correction indicated a signiﬁcant difference between WT
and ΔCRE cells. a, b, e, f, i, j Data shown are representative of more than two independent experiments with similar results. *p < 0.05, **p < 0.01, and
***p < 0.001 (unpaired t-test)
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related genes. Gene ontology analysis shows that ΔCRE
cells showed a signiﬁcant alteration in the levels of ‘cell
adhesion’ and ‘angiogenesis’ such as Nrp2, Pik3cg,
Mmp14, Eng, Adam8 and Adam15 (Fig. 5c, d). In parti-
cular, we found that Ets1 directly regulates Eng and
Mmp14 expression by binding to their cis-regulatory
regions (Fig. 5e, f). Eng encodes Endoglin/CD105, a co-
receptor for transforming growth factor-β (TGF-β) family.
Endoglin (ENG) is known as a critical factor for tumor
invasion by enhancing formation of invadopodia, extra-
cellular proteolysis, chemotaxis, and migration55. Elevated
ENG in breast tumor tissue is associated with higher
metastatic risk and poor prognosis56,57. In addition, ΔCRE
cells showed a signiﬁcant alteration in the levels of matrix
metalloproteinase MMP14 that has an important role in
tumor invasion by regulating the levels of collagens,
extracellular matrix (ECM) proteins and factors involved
in epithelial–mesenchymal transition38,58,59. These ﬁnd-
ings suggest that binding of NFATc2 and NFKB1/RELA
to the CRE might be a key mechanism for enhanced Ets1
expression and increased invasive properties of metastatic
breast cancers. However, we could not rule out other
possibilities involved in this process. Indeed, over-
expression of NFATc2, NFKB1/RELA in ΔCRE cells
partially restored Ets1 expression and invasiveness (Sup-
plementary Figures. S7c, d). These results suggest that
within the CRE region, other region in the Ets1 promoter
may also contain responsive sequences for NFATc2,
NFKB1/RELA. Indeed, we found conserved NFATs/NFkB
binding motifs encompassing −80/−270bp region.
Reporter assay showed this region has promoter activity,
which was enhanced upon stimulation (Fig. 2a). Another
possibility is that NFATc2 and NFKB1/RELA may reg-
ulate invasiveness of cancer cells in an Ets1-independent
manner. Indeed, NFATs are known to promote invasion
by inducing Cox2 expression60. NFKB also affects inva-
siveness of breast cancer cells by regulating CD44 level61.
In summary, our study suggests that the crosstalk
between NFATc2, NFKB1/RELA, and CRE region reg-
ulates Ets1 gene transcription in metastatic breast cancer
cells. Inhibition of this interaction could be a therapeutic
approach to reduce Ets1 levels and Ets1-mediated tumor
invasiveness of breast cancer cells.
Materials and methods
Cell culture, plasmid, and reagents
Cells were cultured in DMEM (WELGENE: LM
001–05) supplemented with 10% FBS (Gibco: 10099–141)
and 100 U/ml of penicillin–streptomycin (Thermo:
15140122). Cells were harvested with 0.05% trypsin-
EDTA (Gibco: 25300–054). Ets1 promoter region (hEts1,
1500 bps) was ampliﬁed with cDNA from MDA-MB-231
cells and inserted into pXPG vector. From this template,
different deletion constructs were prepared by PCR and
cloned into pXPG vector as shown in Fig. 2a. NFAT and/
or NF-κB binding sites in Ets1 promoter were mutated by
QuikChange XL Site Directed Mutagenesis Kit (Agilent:
#200517). hEts1 promoter-ΔNFAT-Luc, or ΔNF-κB-Luc
were constructed by introducing mutations at the con-
sensus NFAT site (TTTTAA→TTCCCGA), or NF-κB
site (TTGGAA→TTAAGGA), respectively. All sequen-
ces were veriﬁed by Sanger sequencing. The following
chemicals were used; phorbol 12-myristate 13-acetate
(PMA, Calbiochem: 524400), Ionomycin (Calbiochem:
407950), Cyclosporin A (Calbiochem: 239835), Decitabine
(Selleckchem: 2353–33–5), and Trichostatin A (Sell-
eckchem: 58880–19–6). All plasmids were obtained from
Addgene (WT-NFAT1: #11100, pREP-NFAT2: #11788,
pREP-NFAT3: #11789, pREP-NFAT4: #11790, pEGFP
NFAT5: #13627, pCMV4-p50: #21965, pCMV4-p52:
#23289, pcDNA-FLAG-REL: #27253, GFP-RelA: #23255,
pcDNA3/Myc-DNMT3A: #35521, pcDNA3/Myc-
DNMT3B1: #35522 and pcDNA3.1 human A3C:
#105047).
RNA isolation, cDNA synthesis, and quantitative RT-PCR
(qRT-PCR)
Total RNA was extracted using TRI Reagent (Molecular
Research Center, Ohio) following standard protocols.
Reverse transcription of 1.0ug of RNA was performed
using oligo (dT) primer (Promega: C1101) with Improm II
Reverse Transcription system (Promega, Madison, WI)
according to the manufacturer’s protocol. Quantitative
RT-PCR was performed using SYBR Green Dye mix
(Takara: RR420) on Rotor-Gene Q (Qiagen, Hilden). Data
were normalized to human hypoxanthine-guanine phos-
phoribosyl transferase (HPRT). Primer sequences are
provided in Supplementary Table 1.
Luciferase reporter assays
Luciferase reporter plasmids containing various regions
of Ets1 promoter were co-transfected with indicated
expression plasmids (such as NFATc2, NFKB1, RELA,
AP-1, and Ets1) in MDA-MB-231 cells using Gene
Expresso (Excellgen: EG-1086) according to the manu-
facturer’s protocol. Renilla luciferase was co-transfected
as an internal control for transfection. After 24 h of
transfection, cells were harvested and luciferase activity
was measured by the dual luciferase assay system (Pro-
mega: E1910) similar to a previous study62.
Nuclear extraction and immuno-blot
Whole cell lysates were extracted using RIPA buffer and
nuclear/cytoplasmic fractions were isolated using nuclear
and cytoplasmic extraction kit (Thermo: 78833) according
to the manufacturer’s protocol. Protein concentration was
measured by Bradford protein assay (Bio-Rad: #5000001)
and 20 μg or 30 μg of proteins were used for SDS-PAGE
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(10%), and then transferred onto a nitrocellulose mem-
brane (Bio-Rad: 162–0097). The following primary anti-
bodies were used from Abcam (Cambridge, UK): anti-
NFATc2 (ab2722), anti-NFKB1 (ab7971), anti-RELA
(ab7970), anti-DNMT3A (ab13888), anti-DNMT3B
(ab13604) and anti-ACTIN (ab3280); Santa Cruz Bio-
technology (Santa Cruz, CA, USA): anti-Ets1 (sc-350);
Cell signaling Technology (Danvers, MA, USA): LaminB1
(#12586); GeneTex (Irvine, TX, USA): APOBEC3C
(GTX102164). Protein expression was visualized with an
ImageQuant™ LAS 4000 (GE healthcare Life Science,
Piscataway, NJ). Actin and LaminB1 expression were
measured as loading controls for whole-cell lysates, and
nuclear protein, respectively. Band intensity was quanti-
ﬁed using ImageJ software (NIH).
Transfection of expression vectors and siRNAs
siRNA-mediated depletion was accomplished using
Scrambled negative control (SR30004), siRNAs for
NFATc2 (SR303150), NFKB1 (SR303161) and RELA
(SR304030) purchased from Origene (OriGene Technol-
ogies, Rockville, MD) using lipofectamine RNAiMAX
reagent (Invitrogen: 13778–100) according to the manu-
facturer’s protocol. After 48 h, transfected cells were used
for the further experiments. Plasmids for NFATc2,
NFKB1, and RELA were transfected into MCF-7 cells
using Gene Expresso (Excellgen: EG-1086) according to
the manufacturer’s protocol.
Chromatin immunoprecipitation (ChIP)-PCR assay
ChIP-PCR assays were performed by Simple ChIP plus
Enzymatic Chromatin IP Kit (Cell Signaling: #9005)
according to the manufacturer’s protocol. Brieﬂy, cells
were cross-linked with 1% of formaldehyde and lysed for
nuclei preparation. Nucleus pellet was treated with
Micrococcal nuclease and sonicated for chromatin frag-
mentation. Protein–chromatin complex was incubated
with antibodies targeting anti-NFATc2 (ab2722), anti-
NFKB1 (ab7971), anti-RELA (ab7970), anti-DNMT3A
(ab13888), anti-DNMT3B (ab13604), anti-H3K4me1
(ab8895), anti-H3K4me3 (ab8580), anti-H3K9me3
(ab8898), anti-Ets1 (Cell Signaling: #14069), anti-H3Ac
(Merck: 06–599), or anti-H3K27me3 (Merck: 07–449) at
4 °C for overnight. Rabbit or mouse IgG (Vector Labora-
tories) was used as negative control. After immunopre-
cipitation, 50 μl of Dynabeads protein G or A (Life
technologies, Oslo) were added and rotated further for 6 h
at 4 °C. Ab/protein/chromatin complexes were reverse-
cross-linked at 65 °C overnight and DNA was puriﬁed by
DNA puriﬁcation columns (Cell Signaling: #10010). The
relative enrichment of speciﬁc regions of precipitated
DNA were measured by real-time PCR (qPCR). To
quantify protein binding in speciﬁc genomic locus,
puriﬁed DNA was used for real-time PCR. Primer
sequences are listed in Supplementary Table 2. H3K27Ac,
and H3K27me3 ChIP-seq data set (GSE38548) were re-
analyzed35.
Bisulﬁte treatment and pyrosequencing
DNA methylation analysis was performed by bisulﬁte
pyrosequencing. Brieﬂy, genomic DNA (200 ng) was
subjected to bisulﬁte treatment with EZ DNA
methylation-Lightning Kit (Zymo Research: D5030).
Bisulﬁte-treated DNA was ampliﬁed using speciﬁc pri-
mers (Supplementary Table 3) with PCR premix (Enzy-
nomics, Korea); PCR conditions: denaturing at 95 °C for
10min, followed by 45 cycles at 95 °C for 30 s, at 55 °C for
30 s, at 72 °C for 30 s, and a ﬁnal extension at 72 °C for
5 min. Subsequently, sequencing was performed on a
PyroMark ID system (Qiagen) with the Pyro Gold reagent
kit (Qiagen: #40–0045). Unmethylated/Methylated con-
trol DNA (Qiagen: #59568/59655) was used as a negative
or positive control.
Chromatin accessibility analysis
Chromatin accessibility was analyzed by EpiQuik
Chromatin Accessibility Assay Kit (Epigentek: #P-1047)
according to the manufacturer’s protocol. Brieﬂy, chro-
matin from MCF-7 or MDA-MB-231 cells was treated
with a nuclease (Nse) mix for 2 min. Nse-treated and No-
Nse control DNA were ampliﬁed by quantitative PCR
with primers targeting speciﬁc region on Ets1 promoter
(Supplementary Table 2). Fold enrichment (FE) was cal-
culated by using the formula FE= 2 (Nse CT-no-Nse CT)
100%.
Deletion of CRE region by CRISPR/Cas9 based KO system
To delete the NFAT and NF-κB binding sites (−540 bp
to −270 bp from TSS) within the core-regulatory element
(CRE; −540 to −80), guide RNA (gRNA) was designed
and mismatch sensitive nuclease assay (T7E1 assay) was
performed for gRNA screening as described previously63.
After screening gRNA, MDA-MB-231 cells were tran-
siently transfected with Cas9 plasmid, gRNA F and gRNA
R with Lipofectamine 2000 (Invitrogen). gRNA sequence
were as follows: F: 5′-ACGCAGGAGCATTACA
TGGGTGG-3′; R: 5′-GGAGCAGTGCGTGGAGCCCC
GGG-3′. After 48 h of transfection, target deleted clones
were screened via genomic DNA analysis. Genomic DNA
was analyzed by PCR and DNA sequencing for selecting
promoter deleted cells. The primer pairs used for PCR
analysis were F: 5′-CAAAGCGAAAGGAAGGGCTG-3′;
R: 5′-GGAGGTAAATTGGAAGCTTACGG-3′. Muta-
tions were conﬁrmed by Sanger sequencing and the
effect of CRE deletion on Ets1 level was tested by
immuno-blot.
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In vitro invasion assay and analysis of lung metastasis
in vivo
For in vitro invasiveness assay, trans-well chamber (8m
pore size; Corning: 354578) and Matrigel (Corning:
354234)-coated membrane were used. Brieﬂy, cells (2.5 ×
104) were seeded in upper chamber containing serum-free
medium and serum-containing medium in lower chamber
as a chemoattractant. After 12 h of incubation, cells on the
lower surface of the membrane were ﬁxed and stained with
the 0.5% crystal violet stain solution to calculate total
number of invaded cells. For lung metastasis assay in vivo,
WT or ΔCRE MDA-MB-231 cells (1 × 106) were intrave-
nously injected into tail vein of 7-week-old nude mice. No
blinding test was done in this study. The injected mice were
killed after 6 weeks to analyze metastasis in lung. The lungs
were ﬁxed in picric acid overnight and the tumor colonies
were counted under a dissection microscope. Animal
experiments were performed in accordance with the guide-
lines and regulations, and with the approval of Institutional
Animal Care and Use Committee (IACUC) at POSTECH.
RNA-sequencing
RNA-sequencing was performed by NextSeq 500
Sequencing System. Total RNA was extracted and pur-
iﬁed with RibospinTMII (GeneAll biotechnology:
314–150). RNA was subjected to library preparation with
TruSeq Stranded mRNA Sample Preparation Kit (Illu-
mina: RS-122–2101~2) and RNA-sequencing was per-
formed by NextSeq 500 Sequencing System (Illumina).
Sequences were mapped to hg19 with TopHat (version
2.0.12). Estimated expression level was generated with
Cufﬂinks (version 2.2.1) and differentially expressed genes
were selected using Cuffdiff (version 2.2.1). RNA-seq was
performed on two biological replicates. The set of differ-
ential expressed genes was analyzed using DAVID gene
functional classiﬁcation tool64. For analysis of gene
expression between MCF-7 and MDA-MB-231 cells
shown in Fig. 4d, raw data from the NCBI database
(GSE48213) were analyzed65.
Analysis of data set for human samples and cell lines
Data of human breast tumor specimens (n= 1100) were
obtained from The Cancer Genome Atlas (TCGA) database
(https://tcga-data.nci.nih.gov/tcga/). mRNA expression data
(RNA Seq V2 RSEM) were obtained through cBioPortal
(http://www.cbioportal.org/). The Human breast cell lines
(n= 59) expression data were obtained from Cancer Cell
Line Encyclopedia (https://portals.broadinstitute.org/ccle).
Spearman correlation coefﬁcients analysis was used to
evaluate the gene expression correlation.
Statistical analysis
Statistical analysis of at least three independent
experiments was performed. Error bars indicates standard
deviation (SD). All student t-tests performed were student
two-tailed tests (*p < 0.05, **p < 0.01, and ***p < 0.001). For
comparisons of more than two groups, data were analyzed
using one-way analysis of variance (ANOVA) and adjus-
ted by the correction of Bonferroni. For data with more
than one independent variable, two-way ANOVA was
used. Data were calculated and graphed with GraphPad
Prism software.
Data accessibility
RNA-seq data sets have been deposited in the GEO
database with accession code GSE106634
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Supplementary Figure 1. Comparative analyses of Ets1 expression between metastatic MDA-
MB-231 and non-metastatic MDA-MB-468 breast cancer cells. (a) Analyses of Ets1 protein and 
transcripts levels by Immuno-blot and qRT-PCR. (b) Cells were stained with crystal violet and 
representative images were obtained from in vitro invasion assay using 10% FBS as chemoattractant. 
Scale bar: 100µm. (c-d) Comparison of trans-acting factors of Ets1 and Ets1 target genes transcript 
and protein levels in MDA-MB-231 and MDA-MB-468 cells determined by (c) qRT-PCR normalized 
against Hprt and (d) Immune-blot. (a-c) Data shown are representative of more than three independent 
experiments with similar results. n.s.; not significant. *P < 0.05, **P < 0.01 and ***P < 0.001 
aSupplementary Fig 2. Kim et al.
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Supplementary Figure 2. In silico analysis of transcription factor binding sites on the Ets1 
promoter region. (a) ECR browser analysis of the human and murine Ets1 gene loci is shown. The 
red boxed region indicates the putative promoter region of the Ets1 gene. The mouse genomic 
sequence is used as the base sequence on the x-axis. The boxed region indicates shared NFATs and 
NFKBs binding sites between human and mouse (matrix similarity: 0.75). (b) 5’-end genomic sequence 
of human Ets1 gene locus with transcription start site (TSS) indicated in black arrow. Translation start 
site (ATG) and putative binding sites for transcription factors (NFAT and NFKB) are indicated and boxed. 
(c) Luciferase reporter assays were performed in the MDA-MB-231 cells transfected with Ets1 promoter-
Luc reporter vector (540bp) and together with indicated combination of expression vectors. Relative 
luciferase activity in response to PMA/Ionomycin stimulation was measured. Data shown are 
representative of three independent experiments with similar results. *p < 0.05, **p < 0.01 and ***p < 
0.001. 
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Supplementary Figure 3. Overexpression of NFATc2, NFKB1/RELA and Ets1 enhances invasion 
properties of MCF-7 cells. (a,b) Invasion assay was performed in MCF-7 cells. Cells were transfected 
with mock or indicated expression vectors individually or in combination. Scale bar: 100µm. (c) MCF-7 
cells were transfected with mock or indicated expression vectors, then enrichment of NFATc2 and 
NFKB1 at Ets1 promoter locus was analyzed ChIP assay. The data from each replicate were normalized 
to the input control and the graphs represent fold enrichment of the indicated proteins to control antibody 
at the designated locus. (a-c) Data shown are representative of more than three independent 
experiments with similar results. n.s.; not significant. *P < 0.05 
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Supplementary Figure 4. Decitabine induces Ets1 expression and invasive properties of MCF-7 
cells. (a) Nuclei isolated from the cells left untreated or stimulated with PMA/Ionomycin (P/I) were 
treated with Nuclease mixture as described in Materials and Methods. Chromatin accessibility by real-
time PCR (CHART-PCR) was performed at the Ets1 promoter in MCF-7 and MDA-MB-231 cells. (b) 
Effect of Decitabine (DNA methyltransferase inhibitor) and TSA (histone acetylation inhibitor) treatment 
in MCF-7 cells on Ets1 transcript level determined by qRT-PCR normalized against Hprt. (c) Analyses 
of Ets1 protein levels by Immuno-blot. (d) Invasion assay after Decitabine (Mock, 10 and 25uM) 
treatment in MCF-7 cells. Scale bar: 100µm. (e) After Decitabine treatment, relative enrichment of 
NFKB1 and RELA to the CRE region determined by ChIP analysis. (a-c) Data shown are representative 
of more than three independent experiments with similar results. *P < 0.05, **P < 0.01 and ***P < 0.001 
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Supplementary Figure 5. DNMT3A/3B and APOBEC3C regulate Ets1 expression through binding 
to Ets1 promoter loci. (a) Chromatin immunoprecipitation analysis of DNMT3A and DNMT3 at Ets1 
promoter locus in MCF-7 cells under unstimulated and P/I stimulation conditions. The data from each 
replicate were normalized to the input control and the graphs represent fold enrichment of the indicated 
proteins to control antibody at the designated locus. (b-c) Analyses of Ets1 protein levels by Immuno-
blot after overexpression of Dnmt3a/3b (b) and Apobec3c (c) in MDA-MB-231 and MCF-7 cells, 
respectively. Relative band intensity of Immuno-blot (b-c) was quantified by Image J software. (d) 
Scatterplots and Spearman's rank correlation from TCGA database. Correlation of Ets1 with Dnmt3a/3b 
and Apobec3c in normal and BRCA mRNA. Each symbol represents an individual human specimen. 
(a,c,d) Data shown are representative of three independent experiments with similar results. n.s.; not 
significant. *P < 0.05, **P < 0.01 and ***P < 0.001 
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Supplementary Figure 6. Generation of CRE region-deleted (ΔCRE) MDA-MB-231 cells. (a) 
Schematic depiction of the CRE region (boxed in black) in the Ets1 promoter locus. The sequence of 
target sites for deletion (-540 to -270bp) within the CRE marked in red color, and for guide RNAs (gRNA) 
forward- and reverse-sites indicated in yellow and green color, respectively. (b) Confirmation of CRE 
deletion by genotyping of WT and ΔCRE MDA-MB-231 cells by PCR with primers shown in the Materials 
and Methods. 
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Supplementary Figure 7. Overexpression of NFATc2, NFKB1/RELA and Ets1 rescues invasion 
properties of ΔCRE cells. (a-b) Effect of Ets1 overexpression of on Ets1 level (a) and invasive 
properties in ΔCRE cells determined by Immuno-blot (a) and Invasion assay (b). (c-d) Effect of 
overexpression of NFATc2 and NFKB1/RELA on Ets1 expression and invasive properties in ΔCRE cells 
was determined by (c) Immuno-blot and (d) Invasion assay. Scale bar: 100µm. Relative band intensity 
of Immuno-blot was quantified by Image J software. Data shown are representative of more than three 
independent experiments with similar results. *P < 0.05, **P < 0.01 and ***P < 0.001 
Table 1. Primer sequences used for qReal-Time PCR 
 
Genes Sequences (5’ - 3’) 
HPRT F: CTGAAGAGCTATTGTAATGACCAG R: TCTTTGGATTATACTGCCTGAC 
Ets1 F: TCACTAAAGAACAGCAACGA R: GGTTTCACATCCTCTTTCTG 
NFATC2 F: TGCATCTAACCCCATCGAGTG R: TGAGGATCATTTGCTGGC 
NFKB1 F: TCTCTATGACCTGGATGACTC R: GTTTCATGTCTCCTTGTGCT  
RELA F: ACA GGA GAA GGG ACG CCA T R: GAA GCC CTA CAG ACG AGC TCA 
ENG F: GTCTCAAGACCAGGAAGTCCA R: CGTGTGCGAGTAGATGTACC 
MMP14 F: TGAGGATCTGAATGGAAATGAC R: CATAAAGTTGCTGGATGCCC 
DNMT3A F: CTCTTTGATGGAATCGCTACAGG R: CCACTCCTGGATATGCTTCTG 
DNMT3B F: CCC TCA CAC TCA GAT CAT CTT CT R: GCT ACG ACG TGG GCT ACA G 
APOBEC3C F: AATCCACAGATCAGAAACCCGA R: CAGTATGTCGTCGCAGAACC 
 
Table 2. Primer sequences used for ChIP PCR 
 
Genes Sequences (5’ - 3’) 
Ets1 F: TCCACCGTTTCGGGAAAGTC R: GTGAATGAATGATGTACACGCAC  
ENG F: CCTCAGCCACTAGAACAAACC R: AGGTGCCACATACTGCTCTC 
MMP14 F: CTGTGTTAATTGCAGGGAG R: CTCCTCAGACAACTCCCAC 
DNMT3A/3B F: GAAAGTCCGTCTGATTCTCCA R: CCTTCATCCACATGCCTCAC 
 
Table 3. Primer sequences used for Pyrosequencing 
 
Locus Sequences (5’ - 3’) 
Ets1(-375)-F ATTATGTTGTTATTGGGAGGG 
Ets1(-375)-R  5’biotin- ACCAATATACAAACTAAATACACAAACC 
Ets1(-375)-S GGGTGATTAAGTTTTTAAGA 
Ets1(-534)-F TGGGTGGGTTTTGAAAAATTGA 
Ets1(-534)-R:  5’biotin- CTCCCAATAACAACATAATTTTCC 
Ets1(-534)-S ATTTTTAAAGTTTTTTGAGGAT 
 
